KCS Wealth Advisory bought a new position in shares of Shire PLC (NASDAQ:SHPG) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,657 shares of the biopharmaceutical company’s stock, valued at approximately $722,000.
Other hedge funds have also modified their holdings of the company. YorkBridge Wealth Partners LLC raised its stake in shares of Shire by 81.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 317 shares in the last quarter. BB&T Investment Services Inc. increased its stake in Shire by 1,672.3% in the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 786 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new position in Shire in the 3rd quarter valued at approximately $159,000. Pacer Advisors Inc. purchased a new position in Shire in the 2nd quarter valued at approximately $171,000. Finally, Stephens Inc. AR increased its stake in Shire by 22.2% in the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 228 shares in the last quarter. 20.19% of the stock is owned by institutional investors and hedge funds.
Several research firms recently weighed in on SHPG. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Shire in a research note on Wednesday, January 3rd. Cantor Fitzgerald set a $222.00 price objective on Shire and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Liberum Capital reaffirmed a “hold” rating on shares of Shire in a research note on Wednesday, December 20th. Cowen set a $225.00 price objective on Shire and gave the company a “buy” rating in a research note on Friday, January 5th. Finally, Royal Bank of Canada reaffirmed a “buy” rating and issued a $213.00 price objective on shares of Shire in a research note on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $212.18.
Shares of Shire PLC (NASDAQ SHPG) traded down $0.86 during trading hours on Friday, reaching $147.55. The company’s stock had a trading volume of 1,098,141 shares, compared to its average volume of 1,202,044. The firm has a market cap of $44,560.00, a PE ratio of 27.79, a PEG ratio of 0.84 and a beta of 1.59. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55. Shire PLC has a 52-week low of $137.17 and a 52-week high of $192.15.
Shire (NASDAQ:SHPG) last announced its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating analysts’ consensus estimates of $3.64 by $0.17. The firm had revenue of $3.70 billion for the quarter. Shire had a return on equity of 14.41% and a net margin of 10.95%. Shire’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter last year, the company posted $3.17 EPS. equities analysts anticipate that Shire PLC will post 15 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “KCS Wealth Advisory Buys Shares of 4,657 Shire PLC (SHPG)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/12/kcs-wealth-advisory-buys-shares-of-4657-shire-plc-shpg.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.